Insulin Degludec (Tresiba®)

Assessment Status Assessment process complete
Drug Insulin Degludec
Brand Tresiba®
Indication Treatment of diabetes mellitus
Assessment Process
Rapid review commissioned 17/12/2012
Rapid review completed 04/01/2013
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 04/11/2014
NCPE assessment completed 04/05/2015
NCPE assessment outcome Reimbursement Not Recommended at the submitted price.

Technical Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.